Page last updated: 2024-12-05

norethandrolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Norethandrolone: A synthetic hormone with anabolic and androgenic properties and moderate progestational activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5858
CHEMBL ID1697845
CHEBI ID135282
SCHEMBL ID147638
MeSH IDM0014968

Synonyms (71)

Synonym
(17beta)-17-ethyl-17-hydroxyestr-4-en-3-one
17-hydroxy-19-norpregn-4-en-3-one
noretandrolona [inn-spanish]
17-alpha-nortestosterone
solevar
19-nor-17-alpha-ethyltestosterone
einecs 200-153-5
19-norpregn-4-en-3-one, 17-hydroxy-, (17alpha)-
u 6817
ethylnortestosteron
17-hydroxy-19-nor-17-alpha-pregn-4-en-3-one
17alpha-ethylnortestosterone
19-norethyltestosterone
17-alpha-ethyl-17-hydroxy-4-norandrosten-3-one
cb 8022
19-norpregn-4-en-3-one, 17-hydroxy-, (17-alpha)-
ccris 9066
17alpha-ethyl-17beta-hydroxyestr-4-en-3-one
noretandrolone [dcit]
17-alpha-ethyl-17-hydroxy-19-norandrost-4-en-3-one
19-nor-17-alpha-pregn-4-en-3-one, 17-hydroxy-
norethandrolonum [inn-latin]
19-nor-17alpha-pregn-4-en-3-one, 17-hydroxy-
17-alpha-ethyl-17-hydroxynorandrostenone
estr-4-en-3-one, 17alpha-ethyl-17-hydroxy-
nsc 70581
17alpha-ethyl-19-nortestosterone
nsc70581
nsc-70581
norethandrolone
19-norpregn-4-en-3-one, (17.alpha.)-
estr-4-en-3-one, 17.alpha.-ethyl-17-hydroxy-
8022 c. b.
sc 5914
17-ethyl-19-nortestosterone
52-78-8
nsc-9893
17.alpha.-ethylnortestosterone
19-nortestosterone, 17-ethyl-
nilevar
17.alpha.-ethyl-19-nortestosterone
19-nor-17.alpha.-pregn-4-en-3-one, 17-hydroxy-
pronabol
17-ent
nileva
nsc9893
D07127
norethandrolone (inn)
CHEBI:135282
(8r,9s,10r,13s,14s,17s)-17-ethyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
CHEMBL1697845
noretandrolona
p7w01638w6 ,
unii-p7w01638w6
norethandrolone [inn:ban:nf]
norethandrolonum
noretandrolone
8022 c.b.
17.alpha.-ethyl-17.beta.-hydroxyestr-4-en-3-one
norethandrolone [mi]
norethandrolone [inn]
norethandrolone [who-dd]
norethandrolone [mart.]
SCHEMBL147638
ZDHCJEIGTNNEMY-XGXHKTLJSA-N
17alpha-ethyl-17-hydroxyestr-4-en-3-one
W-105795
DTXSID0023379
norethandrolone 1.0 mg/ml in acetonitrile
DB12787
Q7050955

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" It is concluded that the dosage administered was inadequate for contraceptive purposes."( Administration of norethandrolone and testosterone as a contraceptive agent for men.
Bernstein, GS; Brenner, PF; Jecht, EW; Mishell, DR; Roy, S, 1975
)
0.59
" Half of the compounds decreased uterine weight at lower doses but increased it at higher doses within the dosage range (1-4000 micrograms/day)."( Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat.
Boris, A; Nelson, EW; Trmal, T, 1972
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (292)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990272 (93.15)18.7374
1990's9 (3.08)18.2507
2000's8 (2.74)29.6817
2010's3 (1.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.99 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index60.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (2.53%)5.53%
Reviews10 (3.16%)6.00%
Case Studies15 (4.75%)4.05%
Observational0 (0.00%)0.25%
Other283 (89.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Adjonction of Androgenotheapy for Post-Remission Treatment of Elderly Patients With Acute Myeloid Leukemia - Results of the Multicenter Goelams SA-2002 Trial. [NCT00700544]Phase 3330 participants (Actual)Interventional2002-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]